eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today

eXoZymes Inc. (NASDAQ:EXOZ) announced a 10-fold productivity increase in its NCT manufacturing process, reducing reaction time by 80% and boosting output per liter by 67%. The company's internal assessments show a 100x reduction in estimated manufacturing costs from the first to the current process. These improvements support scalable commercial production and technology transfer to future partners, according to eXoZymes.

J.P. Morgan raised its 2027 price target for Novo Nordisk (NVO) to 275 DKK from 250 DKK, citing stronger sales forecasts for Ozempic and Wegovy. The broker increased 2026-2030 EPS forecasts by 4-8%, expecting 1% sales growth in 2027. Ozempic's forecast was raised by 8% to 113B DKK, while Oral Wegovy's was cut by 11% to 18B DKK.

Morgan Stanley maintains an Underweight rating on Lululemon (LULU), citing a multi-quarter earnings headwind due to CEO O'Neill's strategic reset. EPS and revenue estimates have been slashed 40% and 7.87% over the past year, respectively. The stock trades at $122.78, down 64% from its 52-week high. Morgan Stanley argues that consensus 2027 growth expectations are too optimistic, as the reset involves short-term pain. Bright spots include China's 25% growth and a strong balance sheet.

BMO Financial Group reported Q3 2026 net income of $1.75B, down 25% YoY, but adjusted net income rose 19% to $2.86B. EPS fell 24% to $2.38, while adjusted EPS increased 22% to $3.96. The bank maintained a CET1 ratio of 13.0% and announced a quarterly dividend of $1.71 per share. CEO Darryl White highlighted strong performance in Capital Markets and Wealth Management, along with improved credit quality.

Citizens maintained a Market Perform rating on Blackstone Mortgage Trust (BXMT) after its Q2 2026 earnings. BXMT reported $1.2B in loan repayments and $1.4B in investments, shifting focus to residential, industrial, and net lease assets. Shares trade at 0.73x book value with a 13.3% dividend yield. Q2 earnings showed distributable earnings of $0.31 per share, missing estimates, but revenue beat forecasts at $158.06M. Book value per share declined 4% to $19.31. Raymond James downgraded BXMT to Ma

Gold Fields reported an 81% rise in profit to $1.85bn for the first half of 2026, driven by higher gold prices and increased production. The company declared an interim dividend of R16.25 per share and allocated $500m for additional shareholder returns, bringing the total to $1.25bn. CEO Mike Fraser attributed the strong performance to increased sales volumes and higher gold prices, with adjusted free cash flow more than doubling. The company remains on track to meet its full-year guidance.